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Seasonal Palmar Keratoderma in Erythropoietic
Protoporphyria Indicates Autosomal Recessive
Inheritance
S. Alexander Holme1, Sharon D. Whatley2, Andrew G. Roberts2, Alexander V. Anstey1, George H. Elder2,
Russell D. Ead3, M. Felicity Stewart4, Peter M. Farr5, Helen M. Lewis6, Nicholas Davies7, Marion I. White8,
R. Simon Ackroyd9 and Michael N. Badminton2
Erythropoietic protoporphyria (EPP) is an inherited disorder that results from partial deficiency of ferrochelatase
(FECH). It is characterized clinically by acute photosensitivity and, in 2% of patients, liver disease. Inheritance is
usually autosomal dominant with low penetrance but is recessive in about 4% of families. A cross-sectional
study of 223 patients with EPP in the United Kingdom identified six individuals with palmar keratoderma. We
now show that these and three additional patients, from six families, have an inherited subtype of EPP which is
characterized by seasonal palmar keratoderma, relatively low erythrocyte protoporphyrin concentrations, and
recessive inheritance. No patient had evidence of liver dysfunction; four patients had neurological
abnormalities. Patients were hetero- or homoallelic for nine different FECH mutations; four of which were
previously unreported. Prokaryotic expression predicted that FECH activities were 2.7–25% (mean 10.6%) of
normal. Neither mutation type nor FECH activity provided an explanation for the unusual phenotype. Our
findings show that palmar keratoderma is a clinical indicator of recessive EPP, identify a phenotype that occurs
in 38% of reported families with recessive EPP that to our knowledge is previously unreported, and suggest that
patients with this phenotype may carry a lower risk of liver disease than other patients with recessive EPP.
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INTRODUCTION
Erythropoietic protoporphyria (EPP) is an inherited disease
characterized by life-long acute photosensitivity with mini-
mal cutaneous signs and occasional liver dysfunction (Todd,
1994; Cox, 2003). It results from partial deficiency of the
enzyme ferrochelatase (FECH) which leads to accumulation
of the photosensitizing pigment, protoporphyrin, in erythro-
cytes, plasma, skin, and liver. Reduction of FECH activity to
below about 35% of normal is required for protoporphyrin to
accumulate sufficiently to cause photosensitivity (Nordmann
and Deybach, 1990). In most families, this decrease is
brought about by coinheritance of a hypomorphic FECH
IVS3-48C allele trans to a FECH mutation that markedly
decreases or abolishes FECH activity (Gouya et al., 2002;
Gouya et al., 2006). The hypomorphic allele is present in
13% of the United Kingdom population (Whatley et al.,
2004). In these families, EPP is inherited as a dominant
disorder with low clinical penetrance (Gouya et al., 2002,
2006). More rarely, EPP may be transmitted as an autosomal
recessive trait with photosensitivity resulting from the
presence of FECH mutations on both alleles (Gouya et al.,
2006). To date, only 12 families with autosomal recessive
EPP have been reported (Lamoril et al., 1991; Sarkany et al.,
1994a; Poh-Fitzpatrick et al., 2002; Whatley et al., 2004;
Gouya et al., 2006; Herrero et al., 2007). Recessive EPP
carries a higher risk of liver disease than the dominant form
(Sarkany et al., 1994a; Whatley et al., 2004; Gouya et al.,
2006; Herrero et al., 2007).
Chronic skin lesions in EPP are the result of repeated
episodes of acute photosensitivity. They are restricted to sun-
exposed areas and rarely amount to more than minor pitting
and scarring of the face with some waxy thickening of the
skin, particularly over the joints on the backs of the hands
(Schmidt et al., 1974; DeLeo et al., 1976; Todd, 1994; Holme
et al., 2006). In a cross-sectional study of 223 patients with
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EPP (Holme et al., 2006), six patients were found to have
palmar keratoderma; a chronic skin condition that had not
previously been recognized as a feature of EPP. Here we show
that these and three additional patients have a previously
unreported inherited subtype of EPP characterized by palmar
keratoderma, relatively low erythrocyte protoporphyrin con-
centrations and autosomal recessive inheritance.
RESULTS
Palmar keratoderma is an uncommon feature of EPP
We identified nine patients with EPP and palmar
keratoderma; five males and four females, aged 8–63 years,
from six families (Table 1). Six of these, from five families,
were identified during a cross-sectional study of the
clinical features of 223 patients with EPP in the UK, of
whom 193 were unrelated, (Holme et al., 2006), giving
prevalences for palmar keratoderma in EPP of 2.7% for all
patients and 2.6% (95% confidence interval: 1.0–5.1%) for
families.
In all patients, hyperkeratosis had been present since early
childhood and in seven patients had developed before the
diagnosis of EPP was made. In three patients the development
of mild palmar keratoderma was preceded during infancy by
a scaly rash, mainly on the dorsum of the hands, initially
thought to be eczema; a third patient has areas of
hyperpigmentation and lichenified skin over her knees, neck,
and elbows which were present before the onset of
photosensitivity and have persisted. Hyperkeratosis was
worse in summer and often resolved in winter. In one
patient, occlusion of the skin with a plaster cast for 6 weeks
following a wrist fracture led to almost complete resolution of
the keratoderma.
The hyperkeratosis ranged in severity from waxy kerato-
derma over the whole palm to mild hyperkeratosis of the first
interdigital web (Figure 1; Table 1). Palmar keratoderma was
sharply demarcated at the wrist with, in most cases, minimal
transgredience onto the extensor surface, and without an
erythematous border (Figure 1). Two patients had mild
onycholysis but otherwise nails were not affected. Sweating
appeared unimpaired. All patients had thickened skin over their
knuckle joints, a sign which is present in 35% of 223 UK
patients with EPP (Holme et al., 2006). This thickening was mild
or moderate in severity. No patient with dominant EPP and
thickened knuckle skin, even those with severe thickening and
scarring, showed any evidence of changes on the palmar
surface. Two unrelated patients also had mild plantar hyper-
keratosis (Table 1). Hyperkeratosis was not particularly marked
at sites of pressure or punctuate in pattern. No patient reported
blistering or hyperhydrosis. Only a very small punch biopsy
from the hand of one patient (patient 2) was examined
histopathologically. The limited amount of epidermis present
was slightly thickened and spongiotic and there were some
prominent upper dermal vessels with a hint of periodic acid
Schiff (PAS)-positive hyaline change. There was not enough
epidermis to determine whether the keratin layer was thickened.
The severity of photosensitivity varied within families but
was similar to that in patients with EPP without keratoderma
(Holme et al., 2006). All became photosensitive between the
ages of 3 and 17 months. Symptoms started within
1–30 minutes after exposure to sunlight and quality of life,
assessed by childhood dermatology quality of life index or
dermatology quality of life index scores (Holme et al., 2006),
was severely impaired in the six patients in which it was
measured (mean scores 12, range 5–18).
Table 1. EPP with keratoderma: clinical features
Family Patient Sex
Age
(years)
Onset age
(years)
Family
history
RBC porphyrin
(lmol l1) Keratoderma
I P1 F 8 1.4 sib1 2.3 Confluent waxy palmar hyperkeratosis with fine peeling;
sharp cutoff at wrists.
P2 M 10 1.0 sib1 2.0 Hyperkeratosis and peeling of first interdigital web and patchy keratosis
and peeling over palmar surface of digit joints and pulps.
II2 P3 F 58 0.5 sib 7.4 Palmar hyperkeratosis with sharp cutoff at wrist; transgredience to involve
first interdigital web; focal plantar hyperkeratosis with fissuring over
heels and MCT joints
P4 M 52 0.4 sib 6.2 Mild hyperkeratosis of first interdigital web.
III P5 M 27 0.3 — 15.5 Confluent palmar hyperkeratosis with peeling; lateral aspects dry, white,
and cracked; slight onycholysis; hyperkeratosis on medial aspect of forefoot
and great toes.
IV P6 M 63 o1 — 7.9 Marked keratosis of first interdigital web and radial border of index fingers
with fissuring at index finger joints.
V P7 F 17 0.25 — 6.8 Waxy keratoderma over the whole palm; mild fine peeling; more obvious
in summer, regresses in winter; sharp cutoff at wrist. Nail dystrophy.
VI P8 M 13 0.25 sib 10.5 Mild hyperkeratosis of first interdigital web.
P9 F 12 2.0 sib 11.2 Mild hyperkeratosis of first interdigital web.
RBC, red blood cell.
1Great grandmother has EPP without keratoderma (see text).
2Consanguineous parents.
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Four patients from three families had neurological
abnormalities. Three patients (P7, P8, P9) had slight or
moderately severe cognitive and motor developmental delay,
without regression since early childhood, and one of these
suffered from fits until the age of 2 years. Older siblings in
both families had neither EPP nor developmental delay. One
patient (P4) presented in his early 30s with a spastic
paraparesis that has progressed; extensive investigations to
identify a cause were negative. Hemoglobin concentrations
and biochemical tests of liver function were normal in all
patients, except for one female patient who had a hemo-
globin concentration of 11.9 g (100 ml)1.
Erythrocyte protoporphyrin concentrations are lower in EPP
with keratoderma than in EPP without keratoderma
Erythrocyte porphyrin concentrations in the 9 patients with
keratoderma (median 7.4 mmol l1, range 2.0–15.5 mmol l1;
normal subjects, 0.4–1.7 mmol l1) were significantly lower
than in 203 patients without keratoderma (median
22.8 mmol l1, range 4.1–159.2mmol l1) (Po0.001). When
two members of the same family were affected, erythrocyte
porphyrin concentrations were similar. The percentage of free
erythrocyte protoporphyrin (41–91%) was increased in all
patients but in those with the lowest total erythrocyte
porphyrin was only approximately equal in amount to
zinc–protoporphyrin. In contrast, the plasma protoporphyrin
concentrations in the patients with keratoderma (median
55.0 nmol l1, range 13.4–115.1 nmol l1; normal subjects,
less than 10.5 nmol l1) did not differ significantly from those
in 11 randomly selected patients with EPP without kerato-
derma (median 68.4, range 18.8–396.0) whose erythrocyte
porphyrin concentrations ranged from 12.4 to 159.2mmol l1
(median 30.1 mmol l1). Fecal total porphyrin excretion was
substantially increased (median 1,198 nmol g1 dry weight;
range 523–1,940 nmol g1; normal subjects, less than
200 nmol g1) in the seven patients in whom it was
measured, with protoporphyrin accounting for greater than
80% of the total.
EPP with palmar keratoderma is inherited in an autosomal
recessive pattern
Three patients had no family history of overt EPP or palmar
keratoderma. In families II and VI, two siblings had EPP with
keratoderma but no other relative had either condition. In
family I, two of three siblings had EPP with keratoderma; the
third had neither condition but their maternal great grand-
mother had a lifelong history of photosensitivity without
keratoderma. Photosensitivity and keratoderma always oc-
curred together when more than one member of the same
generation had EPP and overall keratoderma was not reported
in any family member who did not have EPP.
Mutational analysis showed that all patients with EPP and
palmar keratoderma were either compound heterozygous or
homozygous for FECH mutations and that only one patient
(family III) had inherited the hypomorphic FECH IVS3-48C
allele (Table 2). All but one of the mutations were missense;
four of these (c.0302T4C; c.0854A4G; c.0898G4T;
c.0502C4T) are previously unreported. Mutational analyses
of families II and VI have been reported (Whatley et al.,
2004). Both patients in family I were compound hetero-
zygotes for a missense mutation and a mutation
(IVS3þ 2T4G) that is known to impair splicing of exon 3
(Sarkany et al., 1994b). In their maternal grandmother, this
mutation was trans to an FECH IVS3-48C allele; a genotype
that has been identified in other patients with the typical
dominant form of EPP (Whatley SD, unpublished informa-
tion). Mutational analysis of 184 unrelated patients without
a
b
c
Figure 1. Palmar keratoderma in EPP. For clinical details see Table 1; (a)
patient 7, (b) patient 6, (c) patient 2.
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keratoderma identified 2 additional patients with recessive
EPP; one of whom has been reported previously (Whatley
et al., 2004). The other was homozygous for both a
previously unreported mutation (c.0502C4T; P168L) and
the hypomorphic IVS3-48C allele.
Five of the eight missense mutations that we identified
were expressed in a prokaryotic expression system and their
effect on FECH activity determined (Table 3). These activities,
together with those previously reported for the three other
missense mutations (Whatley et al., 2004), were used to
calculate the FECH activities in our patients (Table 2) on the
assumption that they were similar to those expressed by these
alleles in human tissues.
DISCUSSION
The combination of palmar keratoderma, a relatively low
erythrocyte protoporphyrin concentration and autosomal
recessive inheritance that we describe here in nine patients
from six families constitutes a hitherto unrecognized subtype
of EPP. Of the 13, 2 patients from 12 families with recessive
EPP described previously (Lamoril et al., 1991; Sarkany et al.,
1994a; Poh-Fitzpatrick et al., 2002; Whatley et al., 2004;
Gouya et al., 2006; Herrero et al., 2007) are also included in
this report (P4, P8). Thus, of the 20 symptomatic patients from
16 families with recessive EPP now reported, 9 from 6
families (45% of patients; 38% of families) have palmar
keratoderma. To date we have not seen a patient with
keratoderma who has not had recessive EPP but more patients
need to be studied before the reliability of palmar kerato-
derma as a clinical indicator of recessive EPP can fully be
assessed.
Keratoderma was not reported as a clinical feature of
either dominant or recessive EPP (Schmidt et al., 1974;
DeLeo et al., 1976; Lamoril et al., 1991; Todd, 1994; Sarkany
et al., 1994a; Poh-Fitzpatrick et al., 2002; Gouya et al., 2006)
before our study of 223 UK patients with this disorder (Holme
et al., 2006); possibly because it is uncommon and, unless
large numbers of patients are investigated, the association of
EPP with keratoderma may be regarded as chance, as was
initially the case for two of our families. However, it seems
unlikely that keratoderma has been overlooked in all
previously reported patients with recessive EPP. Where
clinical descriptions have been provided (Lamoril et al.,
1991; Sarkany et al., 1994a; Herrero et al., 2007), it has not
been noted and three of the patients with recessive disease
that we have identified (this report; Whatley et al., 2004) did
not have keratoderma.
Our findings are unlikely to be explained by an association
of two separate disorders. First, the keratoderma of EPP differs
clinically from other syndromes that include palmar kerato-
derma (Itin and Fistarol, 2005). The hyperkeratosis fluctuates,
being worse in summer, tends to be relatively mild on the
Table 2. EPP with palmar keratoderma: FECH genotypes with predicted FECH activities.
Family Allele Mutation Effect FECH IVS3-48
Predicted FECH
activity (%)
I1 1 c.0302T4C L101P T 2.72
2 IVS3+2T4G Splice defect T
II1 1 c.0416A4T Q139L T 18
2 c.0416A4T Q139L T
III 1 c.0503C4T P168S T or C 5.63
2 c.0854A4G Q285R C or T
IV 1 c.0820G4A D274N T 5.9
2 c.0898G4T V300L T
V 1 c.0707G4A C236Y T 6.4
2 c.0820G4A D274N T
VI1 1 c.1137C4G K379N T 25
2 c.0707G4A C236Y T
FECH, ferrochelatase.
Previously unreported mutations are shown in bold.
1Both affected siblings had the same genotype.
2Assuming no activity from the IVS3+2T4G allele.
3Assuming IVS3-48C cis to P168S (see text). Predicted FECH activity was calculated from data in Table 3 and Whatley et al. (2004).
Table 3. Prokaryotic expression of mutant and wild
type FECH alleles
FECH allele
FECH activity
(nmol h1mg1)1
Percent wild-type
activity
Wild type 5626 100
L101P 233 5.3
P168S 717 16
D274N 30 0.8
Q285R o10 o1
V300L 489
11
FECH, ferrochelatase.
1Zinc–mesoporphyrin.
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soles, and may almost disappear with complete exclusion of
light; all of which suggest a role for UV exposure in its
etiology. This is supported by the observation that those
with mild involvement have signs only in the first interdigital
web. None of our patients described blistering, suggesting a
nonepidermolytic pattern; none had hyperhydrosis, the
keratosis was not particularly at sites of pressure, and was
not punctuate in pattern. Second, we observed hyperkeratosis
only in recessive EPP and no family showed independent
inheritance of the two conditions. Third, the allelic
heterogeneity of our patients makes close linkage with a
previously undescribed recessive form of keratoderma
very unlikely and fourthly the incidence of inherited
keratoderma in normal populations has been estimated at
between 0.05 (Gulati et al., 1997) and 0.55% (Gamborg
Nielsen et al., 1994) whereas it was present in 2.7% of our
EPP population.
Our patients with keratoderma also differed in other
respects from other patients with autosomal recessive or
dominant EPP. Erythrocyte protoporphyrin concentrations
were lower and, in family I, concentrations were increased by
such a small amount (total erythrocyte porphyrin: 2.0 and
2.3 mmol l1) that the diagnosis would not have been made
without plasma and fecal porphyrin measurements. In spite of
the relatively low erythrocyte concentrations, plasma por-
phyrin concentrations were the same as in EPP without
keratoderma, photosensitivity was severe and fecal proto-
porphyrin concentrations were substantially increased. These
features suggest that our patients may be producing proto-
porphyrin in amounts that are similar to those in EPP without
keratoderma but the explanation for their low erythrocyte
protoporphyrin concentrations is unknown.
There may also be clinical differences apart from
keratoderma. Neurological abnormalities were present in
four of our patients but, apart from a reversible polyneuro-
pathy after transplantation for protoporphyric liver failure
(McGuire et al., 2005), have not previously been described as
associated with any form of EPP. Developmental delay has
been reported in the recessive or ‘‘homozygous’’ forms of the
dominant acute porphyrias, usually in association with other
neurological and skeletal abnormalities (Elder, 1997), which
were not seen in our patients. Also, 5 of the 12 (42%)
reported patients with autosomal recessive EPP, in which
keratoderma was apparently not present, had liver disease
(Sarkany et al., 1994a; Whatley et al., 2004; Gouya et al.,
2006; Herrero et al., 2007). In contrast, none of our nine
patients had liver dysfunction. This raises the possibility that
patients with keratoderma may be at lower risk of liver
disease than other patients with recessive EPP. Liver disease is
accompanied by markedly increased erythrocyte protopor-
phyrin concentrations though it is not clear whether these are
present before liver function deteriorates and their role as a
risk factor for liver disease is uncertain (Bloomer, 1988;
Meerman, 2000). The relatively low erythrocyte porphyrin
concentrations and apparently effective biliary elimination of
protoporphyrin shown by our patients may indicate the
presence of a special pattern of porphyrin metabolism
that does not lead to excessive hepatic accumulation of
protoporphyrin. However, only prolonged follow-up can
determine whether a lower risk of liver disease is another
component of the syndrome that we describe.
The unusual phenotype that we describe here is inherited
in a recessive pattern but it is not clear why it is restricted to
this type of EPP or present in only about 40% of such families.
Although FECH mutations on both alleles appear to be
essential for its expression, it seems unlikely that the
phenotype is determined solely by the nature of the mutations
at the FECH locus. There appear to be no features of the
genotypes shown in Table 2 that clearly distinguish them
from those of other patients with recessive EPP (Whatley
et al., 2004; Gouya et al., 2006). Most mutations are
missense; most are on FECH IVS3-48T alleles and the nine
different mutations are not clustered together in the FECH
molecule (Wu et al., 2001). In four families, one of the
mutations has been identified previously either in dominant
EPP (IVS3þ2T4G) (Sarkany et al., 1994b) or in recessive
EPP without keratoderma (P168S, D274N) with the D274N
mutation being present in two of our families and in two of
those reported by Gouya et al. (2006). Another mutation
(P168S) was present in two of our patients; a homozygote
without keratoderma where it occurred on a hypomorphic
allele and a compound heterozygote with keratoderma
(Table 2), the only one of our patients with a hypomorphic
allele, presumably again containing this mutation. The four
other mutations have only been reported in EPP with
keratoderma. FECH genotype is the main determinant of
FECH activity in EPP (Gouya et al., 2006). In general, FECH
activities in recessive EPP are lower than in dominant EPP
though the presence on one or both alleles of a missense
mutation that has only a small effect on FECH activity may
lead to activities within the range for dominant EPP (Gouya
et al., 2006). Prokaryotic expression of the missense
mutations predicted FECH activities for our patients with
keratoderma of 1–25% (mean 10%) normal (Table 2 and
Table 3; Whatley et al., 2004), close to the range of 4–29%
reported for autosomal recessive EPP (Gouya et al., 2006).
Thus it seems unlikely that the unusual phenotype shown by
our patients is directly determined either by FECH genotype
or expression.
MATERIALS AND METHODS
Patients
The study was conducted in accordance with the Declaration of
Helsinki ethical principles for medical research involving human
subjects and its subsequent amendments. Prior approval was
obtained from the North West Multicentre Research Ethics Commit-
tee and 84 local research ethics committees. All patients or their
parents gave informed consent, including consent for publication of
photographs. Six of the patients with palmar keratoderma were
identified during a cross-sectional study of EPP in the United
Kingdom during which the clinical features of 223 patients from 193
families were noted by the same investigator (SAH) (Holme et al.,
2006). Two additional patients were referred to SAH; one other was
a sibling of a patient included in the cross-sectional study. Blood
samples were obtained from all patients with keratoderma and from
203 EPP patients who did not have keratoderma (Holme et al.,
www.jidonline.org 603
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2006). Quality of life was assessed using dermatology-specific
questionnaires (Holme et al., 2006).
DNA analysis
Genomic DNA was extracted from whole blood using the QIAamp
DNA purification kit (Qiagen, Crawley, UK). For identification of
FECH mutations and SNPs, all exons with 20–300 bp flanking
sequence and 1,300 bp of the promoter region of the FECH gene
were PCR amplified (primers and conditions are available from the
authors) and sequenced. For sequencing, PCR-amplified double-
stranded DNA was purified from agarose gels using the QIAquick gel
extraction kit (Qiagen) before being cycle sequenced using
fluorescent ddNTPs (BigDye) and an ABI Prism 3100 Genetic
Analyzer (PE Biosystems, Warrington, UK). The presence or absence
of mutations was confirmed by sequencing both strands. Partial or
complete FECH gene deletions were excluded in apparent homo-
zygotes by quantitative gene dosage analysis (Wood et al., 2006).
Nucleotides are numbered from the cDNA sequence of human
FECH (GenBank accession number D00726) with the A of the ATG
initiation codon as ‘‘þ 1’’.
Prokaryotic expression of missense mutations
The effect of mutations on FECH activity was determined using the
bacterial expression vector pHisTF20E (Burden et al., 1999).
Mutations were created using the Quickchange mutagenesis
protocol (Stratagene, Stockport, Cheshire, UK) with 50 ng of vector
and 12 cycles of 30 seconds denaturation at 95 1C, 30 seconds
annealing at 55 1C and 8 minutes extension at 68 1C. Primer
sequences are available from the authors. After digestion with DpnI
to eliminate the template vector DNA, the PCR products were used
to transform chemically competent E. coli JM109. Colonies were
screened by automated fluorescent DNA sequencing.
For each mutation, a single bacterial colony was grown in 5 ml of
Luria-Bertani broth containing 100 mg ml1 carbenicillin for 6 hours.
A 25ml aliquot was then used to inoculate 25 ml Luria-Bertani
(100mg ml1 carbenicillin) and the culture grown at 37 1C for
18 hours. Cells were harvested by centrifugation at 6,000 g for
15 minutes and resuspended in 1.5 ml of 50 mM Tris/HCl (pH 7.6)
containing 20% glycerol and 1 mM phenylmethylsulphonyl fluoride.
Cells were disrupted by sonication on ice (3 30 seconds) and
centrifuged at 13,500 g for 2 minutes. The supernatant, which
contains the recombinant FECH, was stored at 70 1C. FECH
activity was determined as described by Gouya et al. (2006). A blank
without cell lysate was included and endogenous bacterial FECH
activity was assayed using an empty vector control. Protein
concentrations were determined using the BCA protein assay (Pierce,
Cramlington, Northumberland, UK).
Other methods
Porphyrins in erythrocyte, plasma, and feces were determined by
standard methods (Deacon and Elder, 2001). Percentages of
protoporphyrin and its zinc chelate were determined by fluores-
cence emission spectroscopy of ethanol extracts of whole blood,
using protoporphyrin and zinc–protoporphyrin as standards.
Statistical methods
Data were analyzed using Microsoft Excel and Minitab v 13.
Measurements were expressed as medians and ranges. The
significance of differences between quantitative variables was
assessed by the Mann–Whitney test.
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